Dear Colleagues

Radiation treatment in particular of prostate cancer is rapidly evolving. During the last decades, enormous progress has emerged due to the coordinated research of physicists, engineers, computer and imaging specialists and physicians. Today, the arsenal of "high precision or targeted radiotherapy" includes multimodal imaging, in-vivo dosimetry, Monte-Carlo calculation techniques of dose planning, patient immobilization techniques, intensity modulated radiotherapy (IMRT), image guided radiotherapy (IGRT), biological adapted radiotherapy (BART), quality assurance, novel methods of brachytherapy and at the far end of the scale, particle beam radiotherapy using protons or carbon ions. Each of these approaches is like a puzzle piece that needs to be put together to provide the patient with high-level optimized radiation treatment.

The advanced technologies in prostate cancer treatment are being utilized more and more in radiation oncology departments worldwide. The introduction of these new techniques is changing target volume definitions and fractionation schedules. This conference aims to provide an overview on current and future concepts in radiation therapy of prostate cancer, including imaging and target delineation, tools ensuring high precision in treatment delivery and various treatment modalities. Controversies such as whether to treat or not treat pelvic lymphatics in locally advanced disease or the use of protons and heavy ions will be highlighted. Lectures will be given by international experts in the field. We are looking forward to hosting you in the springtime in the Bavarian capital with its charming environment and its wonderful mixture of tradition and high-tech.

Congress Venue:
Klinikum rechts der Isar, Technische Universität München, Hörsäle (Lecture halls)
Ismaninger Str. 22, 81675 Munich, Germany

Organization:
Department of Radiation Oncology
Technische Universität München
PD Dr. Hans Geinitz

For registration and further information please visit: www.prostate-radiation-oncology.de
Contact: vokativ GmbH, roc@vokativ.de
T: 0049-551-48857-409

The congress fee includes the pre-conference and a social dinner on Friday April 1, 2011.

Early bird registration (until January 31, 2011):
  150 Euros, late and onsite registration: 200 Euros
Students
Early bird registration (until January 31, 2011):
  50 Euros, late and onsite registration: 70 Euros

CME points: Pre-conference 3 points
Main conference 13 points
(Bayerische Landesärztekammer)
Pre-Conference on Special Scientific Issues

Thursday, March 31

15.00   Welcome address
Michael Molls, Chair Department of Radiation Oncology TU Munich

15:00 - 15:20 Microenvironment
Chairs: M. Horsman, G. Multhoff
Blood flow and hypoxia in prostate cancer
P. Vaupel, Munich

15:30 - 15:50 Therapeutic targeting of the vasculature in prostate cancer
M. Horsman, Aarhus
Stress proteins and radiation resistance
G. Multhoff, Munich

16:10 - 16:30 Coffee break

16:30 - 16:50 Molecular targets and markers
Chairs: M. Maders, P. Vaupel
Prostate molecular targeting and radioresistance
M. Maders, Dresden

17:10 - 17:30 Discussion
H. Kübler, Munich

17:30 - 17:50 Closing remarks

18.00   End of pre-conference

Conference-Program

Friday, April 1

08:30 - 08:50 Welcome address
Wolfgang Herrmann, President TU Munich
Michael Molls, Chair Department of Radiation Oncology TU Munich

08:50 - 09:10 Imaging and delineation
Chairs: A. Gross, M. Schweiger
Prostate imaging modalities: MRI – the gold standard?
A. Gross, Freiburg
PET - advantages and limitations
A. Gross, Freiburg
Organ contouring for IMRT
D. Böhmer, Berlin

09:40 - 09:55 Phase contrast X-ray imaging: Future visualization of 1 millimeter tumors
F. Pfeiffer, Munich

09:55 - 10:15 Discussion

10:15 - 10:35 Coffee break

10:35 - 10:50 Coffee Break

10:50 - 11:05 Brachytherapy
Chair: R. Pötter, A. Andratschke
Principles of 3D, highly conformal brachytherapy
N. Zamboglou, Offenbach
Seed implantation – why
M. Guckenberger, Würzburg

11:05 - 11:20 Discussion

11:20 - 11:35 Hypofractionation
Chairs: M. Roach, C. Bolka
Techniques of pelvic lymphatic irradiation
U. Ganswindt, Munich
Curative treatment of the pelvic lymphatics, pro
M. Roach, San Francisco
Curative treatment of the pelvic lymphatics, contra
P. Pommer, Lyon

11:55 - 12:15 Discussion

12:15 - 12:25 Discussion

12:15 - 12:35 Hormonal therapy for dose escalated patients, pros and cons
M. Bolla, Gronoble

12:35 - 13:00 Discussion

13:00 - 14:20 Lunch and industrial exhibition

14:20 - 14:40 Definitive treatment
Chairs: E. Hug, M. Molls
Dose escalation – an update on randomized trials
H. Budach, Düsseldorf
Is IMRT the new standard?
M. Zelefsky, New York

14:40 - 15:00 Discussion

15:00 - 15:20 Is IGRT the new standard?
P. Kupelian, Los Angeles

15:20 - 15:40 Discussion

15:40 - 16:00 Coffee Break

16:00 - 16:15 Brachytherapy
Chair: G. Biti, N. Zamboglou

16:15 - 16:30 Seed implantation – why
M. Fientje, Würzburg

16:30 - 16:45 HDR brachytherapy – why?
A. Grön, Berlin

16:45 - 17:05 Discussion

17:05 - 17:25 Coffee break

13:00 - 13:20 Hypofractionation
Chair: M. Flentje, G. Arcangeli
Hypofractionation in prostate cancer – biological aspects
N. Andratschke, Munich
Hypofractionation - clinical data
G. Arcangeli, Rome

13:25 - 13:40 Discussion

13:40 - 14:00 Simultaneous integrated boost techniques - update and Munich data
H. Geinitz, Munich

14:00 - 14:20 Discussion

14:20 - 14:40 Proton therapy for prostate cancer: Technological and clinical aspects
E. Hug, Villingen

14:40 - 15:00 Discussion

15:00 - 15:20 Proton therapy for prostate cancer: Biological aspects
J. Debus, Heidelberg

15:20 - 15:40 Discussion

15:40 - 16:00 Tracking and other IGRT modalities
P. Kupelian, Los Angeles

16:00 - 16:20 Discussion

16:20 - 16:30 Coffee Break

13:00 - 13:20 Proton therapy for prostate cancer: Technological and clinical aspects
E. Hug, Villingen

13:25 - 13:40 Discussion

13:40 - 14:00 Proton therapy for prostate cancer: Biological aspects
J. Debus, Heidelberg

14:00 - 14:20 Discussion

14:20 - 14:40 Proton therapy for prostate cancer: Radiobiological aspects
J. Debus, Heidelberg

14:40 - 15:00 Discussion

15:00 - 15:20 Proton therapy for prostate cancer: Radiobiological aspects
J. Debus, Heidelberg

15:20 - 15:40 Discussion

15:40 - 16:00 Proton therapy for prostate cancer: Radiobiological aspects
J. Debus, Heidelberg

16:00 - 16:20 Discussion

16:20 - 16:30 Coffee Break

Saturday, April 2

09:00 - 09:15 Controversy: Image guidance
Chairs: V. Rudich, J. Debus
Is daily imaging necessary for IGRT in prostate cancer - pros and cons
N. Duma, Munich

09:15 - 09:30 Cone Beam CT vs. (MV)-CT
P. Kneschaeur, Munich

09:30 - 09:50 Tracking and other IGRT modalities
P. Kupelian, Los Angeles

09:50 - 10:10 Discussion

10:10 - 10:30 Coffee Break

10:30 - 10:45 Adjutant treatment and salvage treatment
Chairs: T. Weigel, H. Geinitz
Is the target volume clearly defined in post-operative radiotherapy?
M. Stuschke, Essen

10:45 - 11:05 Randomized trials for adjuvant radiotherapy: Update
T. Weigel, Ulm

11:05 - 11:20 Salvage radiotherapy after radical prostatectomy: A second chance?
F. Zimmermann, Basel

11:20 - 11:35 Salvage prostatectomy after radical radiotherapy: A second chance?
H. Kübler, Munich

11:35 - 11:55 Discussion

11:55 - 13:30 Lunch and industrial exhibition

13:30 - 13:50 Controversy: Image guidance
Chairs: M. Brada, M. Stuschke
Is daily imaging necessary for IGRT in prostate cancer - pros and cons
N. Duma, Munich

13:50 - 14:10 Proton therapy for prostate cancer: Technological and clinical aspects
E. Hug, Villingen

14:10 - 14:30 There is evidence for the superiority of protons or heavy ions, contra
J. Debus, Heidelberg

14:30 - 14:45 Discussion

14:45 Closing Remarks